pmlive.com
Cure8 news brief
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
Medications
Mirikizumab
IL-23 inhibitor
Abdominal Pain
Urgency
FDA Approval
Adult patients
Patients On Biologics
Why This Matters
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in clinical remission and endoscopic healing at one year.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease, patients who previously had inadequate response or intolerance to corticosteroids, immunomodulators or biologics, gastroenterologists, and IBD researchers.
Study Snapshot
Story typeCompany update
Evidence typeFDA Approval
Source depthFull source text
What To Know
The FDA has approved Eli Lilly’s Omvoh (mirikizumab-mrkz/mirikizumab) for adults with moderately to severely active Crohn’s disease based on positive results from the Phase 3 VIVID-1 trial.
The approval follows earlier US approval of Omvoh for moderately to severely active ulcerative colitis and a recent positive recommendation from the EMA committee for Crohn’s disease.
VIVID-1 met its primary endpoints including clinical remission and endoscopic healing at one year versus placebo, and an open-label extension (VIVID-2) has reported sustained responses with additional treatment. The drug targets the interleukin-23 p19 subunit (IL-23 p19), an immune pathway involved in gut inflammation.
What this report does not provide are full trial protocols, detailed safety results, or prescribing information — consult official FDA labeling and your treating clinician for how this might apply to individual care.
Keep In Mind
Regulatory approval is based on VIVID-1 and supporting extension data; the article summarizes trial-level outcomes but does not include full safety tables or prescribing details. Decisions about treatment choice or switching should be made with a clinician using the official FDA label and individual patient factors.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationpmlive.com
Indexed viaBing News
Source typeCompany update
PublishedJan 16, 2025, 4:36 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
Eli Lilly's Omvoh granted FDA approval to treat Crohn's disease in adults - PMLiVE
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...
Lilly secures FDA approval for Omvoh to treat Crohn's disease
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.